U.S. drug companies have made $53 billion in licensing deals with Chinese biopharma firms since 2020—redirecting investment away from U.S. research hubs and deepening dependence on the Chinese Communist Party (CCP) for early-stage innovation.
Chinese biotech companies now supply roughly one-third of the new compounds entering U.S. drug pipelines, up from virtually zero five years ago, and are on track to reach 35% of FDA approvals by 2040.
American multinationals increasingly rely on China for faster, cheaper early-stage trials and manufacturing, embedding nearly 80% of surveyed U.S. biotech firms inside a supply chain that U.S. intelligence identifies as tied to the CCP’s military-civil fusion (MCF) strategy.
Without decisive action – including restricting exposure to CCP-linked firms, rebuilding domestic R&D capacity, and lowering U.S. development costs—the United States risks outsourcing the front end of its pharmaceutical ecosystem to its primary strategic competitor.
Read the article.